Julie Maréchal-Jamil: The Biosimilars Market in Europe

Video

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the state of the EU biosimilars market.

Transcript

So I think what’s very important to notice is that biosimilars are used everywhere, in every country. And I think this is important; we’ve had 28 countries until now, and I think it's important to see they are used by every healthcare system.

The nuance in there is that they are used in a variable fashion. So between countries you see a massive difference, and within countries you also see massive differences between the different biosimilars available.

Related Videos
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2023 MJH Life Sciences

All rights reserved.